Visiting from the United States? GLPInfo has a North American edition with US channels and dollar prices: open the US edition. Canada follows in a later release.

Coverage: what the pipeline tracker includes

GLPInfo does not claim to track every medicine or to scan the whole internet. This page lists the medicines in scope, the jurisdictions covered and when each record was last checked, so readers can judge the tracker's completeness for themselves.

Jurisdictions

United Kingdom (MHRA, with NICE and NHS funding recorded separately), United States (FDA) and the European Union (EMA and European Commission). EU authorisation does not mean approval in every European country; Switzerland and other non-EU markets are not yet covered.

Medicines in scope

MedicineTierUK recordsUS recordsEU recordsLast checked
AmycretinP0000Not yet
CagriSema (cagrilintide and semaglutide)P001013 Sep 2026
DulaglutideP001013 Sep 2026
EloralintideP0000Not yet
LiraglutideP002013 Sep 2026
MazdutideP0000Not yet
OrforglipronP001013 Sep 2026
RetatrutideP012113 Sep 2026
SemaglutideP014113 Sep 2026
TirzepatideP003013 Sep 2026

Tier P0 medicines are covered from launch; P1 candidates (survodutide, pemvidutide, VK2735, MariTide and others) are added after each programme is verified. A record count of zero means no verified event has been entered yet, not that nothing has happened.

Sources

Regulators (FDA, MHRA, EMA and the European Commission), trial registries (ClinicalTrials.gov, EU CTIS, ISRCTN), peer-reviewed research and named congress abstracts, sponsor announcements (labelled as company-reported), and access bodies (NICE, NHS England, SMC, CMS). Journalism is used to discover stories; medical and regulatory claims are sourced to original evidence. The daily monitoring service and its per-source health report are in build; until it runs, records are checked by hand and dated above.

Corrections

Every event carries a "Report a correction" link. Corrections update the affected record, its version history and any linked article. See how to report an error.